JNJ News 103.32 06/12/2014 05:08:20 Johnson & Johnson (JNJ)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 103.32 $JNJ

Relapsed Multiple Myeloma - Pipeline Review, H1 2014
M2 - 1 hr 36 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hg9nqn/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Kyowa Hakko Kirin - Sanofi - Eli Lilly and Company - GlaxoSmithKline - Genentech - Piramal Enterprises - Prolexys - Millennium - Novartis - Astellas - Exelixis - Celgene - Threshold - Synta - Acceleron - Altor BioScience - Arno - Stemline - Noxxon - Acetylon - Pharma - Janssen - AbbVie - Oncopeptides - Senhwa Biosciences For more information visit http://www.researchandmarkets.com/research/hg...d_multiple

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - 2 hrs 27 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell

Jim Cramer's 'Mad Money' Recap: Forget Washington and Stay the Course
at The Street - Wed Jun 11, 7:20PM CDT
Nothing turns buyers into sellers faster than wrangling in Washington, Cramer says.

Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs  in 2013. Big drug companies, such as AbbVie,  Johnson & Johnson  , and Amgen  , offer...

Final Glance: Pharmaceuticals companies
AP - Wed Jun 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Final Glance: Medical Devices companies
AP - Wed Jun 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:

Is Medtronic a Buy? What Analyst Day Revealed
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jun 11, 4:05PM CDT
Medtronic 's June 6 analyst day was by no means light fare, as the company crammed quite a bit of information into more than seven hours. While action-oriented investors are likely disappointed that management's commentary would seem to...

Aduro BioTech Secures $55 Million Series C Financing
Business Wire - Wed Jun 11, 3:00PM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development Corporation (JJDC) joined the Morningside group and other new and existing investors in the transaction.

Midday Glance: Pharmaceuticals companies
AP - Wed Jun 11, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Midday Glance: Medical Devices companies
AP - Wed Jun 11, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 1 p.m.:

Stage Set for FIFA World Cup: 2 Sponsors in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 11:36AM CDT
As the stage is set for the FIFA World Cup 2014 kickoff , 32 participating teams along with 22 corporate sponsors are fine-tuning their plans to make this mega event a grand success.

Early Glance: Pharmaceuticals companies
AP - Wed Jun 11, 9:35AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Early Glance: Medical Devices companies
AP - Wed Jun 11, 9:35AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:

2014 Report on the International Infusion Pumps & Accessories (Diabetes, Chemotherapy, Nutrition, Pain Management) Market - Forecasts to 2018
M2 - Wed Jun 11, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg9l76/infusion_pumps) has announced the addition of the "2014 Report on the International Infusion Pumps & Accessories (Diabetes, Chemotherapy, Nutrition, Pain Management) Market - Forecasts to 2018" report to their offering. Infusion pumps and accessories have evolved from regular pumps to modern, automated, integrated, and flexible pumps to meet patient compliance requirements and also provide cost-effective treatment. The safety and quality of infusion pumps and accessories have also gained greater importance in the healthcare market over the years. In this report, the global infusion pump and accessories market is broadly segmented by product, application, and end user. The market, depending on the type of product, is further segmented into devices (pumps) and accessories/disposables. The accessories/disposables are further subdivided into dedicated disposables and non-dedicated disposables. On the basis of the application area, the market is categorized into diabetes, chemotherapy/oncology, gastroenterology, hematology, analgesia/pain management, pediatrics/neonatology, and others. Based on end users, the market is divided into hospitals, home care, and others. Over the past few years, the infusion pumps and accessories market has witnessed a stable growth rate. By 2018, the market is expected to grow at a CAGR of 5.7% from 2013 to 2018 to reach $9,427 million. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insight 4 Market Dynamics 5 Infusion Pumps & Accessories Market, By Product 6 Infusion Pumps And Accessories Market, By Application 7 Infusion Pumps And Accessories Market, By End User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - B. Braun Melsungen Ag - Baxter International Inc. - Carefusion Corporation - Fresenius Se & Co. Kgaa - Hospira, Inc. - Johnson & Johnson - Medtronic, Inc. - Moog Inc. - Smiths Medical - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/cg...sion_pumps

Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire Europe - Wed Jun 11, 12:44AM CDT
Jazz Pharmaceuticals plc today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.

Sabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA)
PR Newswire Europe - Tue Jun 10, 10:13PM CDT
HAMBURG, Germany, May 13, 2014 /PRNewswire/ --

Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 5:45PM CDT
Pharmacyclics (PCYC) announced that the FDA will review its Imbruvica sNDA on a priority basis.

Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Brands' Strategic Moves for Growth and Innovation

Updated Category News Views 506

Fortune Brands Embraces Change for Future Growth Fortune Brands Innovations, Inc. (NYSE: FBIN), a leading innovation company committed to transforming spaces into havens, has announced pivotal changes aimed at enhancing its growth opportunities. These strategic moves reflect the company's dedication to innovation and efficiency as it positions itself for future success....

Continue Reading
Robert Webb's Insightful Stock Options Exercise at NHI

Updated Category News Views 97

Robert Webb Exercises Stock Options at National Health Investors Recently, an important SEC filing revealed that Robert Webb, a Board Member at National Health Investors (NHI), has exercised a significant number of stock options. Key Highlights: The latest Form 4 filing shows that Webb exercised stock options for 70,000 shares of NHI, amounting to a remarkable $1,585,550....

Continue Reading
Palantir Technologies Inc. Increases Investment in UK Defense

Updated Category News Views 271

Palantir Technologies Inc. Stock Update Recently, shares of Palantir Technologies Inc. (NASDAQ: PLTR) saw an increase of 1.58% in pre-market trading following the announcement of a substantial deal with the U.K. government. Strategic Investment in UK Defense This exciting new partnership involves Palantir committing up to £1.5 billion, equivalent to approximately $2...

Continue Reading
Investigation of Varonis Systems, Inc.: A Call to Investors

Updated Category News Views 165

Investigation into Varonis Systems, Inc. Edelson Lechtzin LLP, a well-respected national law firm, is actively investigating Varonis Systems, Inc. (NASDAQ: VRNS) due to potential violations of federal securities laws. This investigation arises from troubling allegations regarding the company's financial disclosures and communication with investors. Varonis Systems,...

Continue Reading
Error Notification on NAV Values in Wealth Invest Fund

Updated Category News Views 127

Error Notification Regarding NAV Values Nasdaq Copenhagen A/S Nikolaj Plads 6 1067 København K Important Information The latest update relates to incorrect NAV values published for the I&T Nordiske Aktier Large Cap division (ISIN: DK0061276656) of Investeringsforeningen Wealth Invest during a specific time frame. Details of the NAV Error This error occurred from 09:45 on...

Continue Reading